This company has been marked as potentially delisted and may not be actively trading. NASDAQ:HUGE FSD Pharma (HUGE) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About FSD Pharma Stock (NASDAQ:HUGE) 30 days 90 days 365 days Advanced Chart Get FSD Pharma alerts:Sign Up Key Stats Today's Range$0.23▼$0.2350-Day Range$0.08▼$0.2052-Week Range$0.07▼$1.68VolumeN/AAverage Volume10.14 million shsMarket Capitalization$9.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewFSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.Read More… Receive HUGE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for FSD Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address HUGE Stock News HeadlinesWall Street bets that Musk will take advantage of Trump and already values Tesla at three times the combined value of the top ten European manufacturersNovember 14, 2024 | msn.comWhat the NFL Draft Can Teach Investors About Big PharmaNovember 12, 2024 | wsj.comThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.June 15, 2025 | Brownstone Research (Ad)Tesla extends post-election rally after Wedbush boosts its price targetNovember 11, 2024 | seekingalpha.comZealand Pharma Gains as JPMorgan Flags $10 Billion OpportunityNovember 8, 2024 | bloomberg.comBig Pharma’s Obesity Bonanza Faces New TestsNovember 4, 2024 | msn.comWhy Elon Musk’s Robotaxi Dreams Are PrematureNovember 2, 2024 | finance.yahoo.comTesla: Profitability Increases Should Drive Stock HigherOctober 24, 2024 | seekingalpha.comSee More Headlines HUGE Stock Analysis - Frequently Asked Questions How were FSD Pharma's earnings last quarter? FSD Pharma Inc. (NASDAQ:HUGE) issued its earnings results on Tuesday, November, 14th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.11. What other stocks do shareholders of FSD Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that FSD Pharma investors own include Meta Platforms (META), SNDL (SNDL), AMC Entertainment (AMC), Ford Motor (F), NVIDIA (NVDA), Fiverr International (FVRR) and NIO (NIO). Company Calendar Last Earnings11/14/2023Today6/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryN/A Current SymbolNASDAQ:HUGE CIK1771885 Webfsdpharma.com Phone(416) 854-8884FaxN/AEmployees17Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.26) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$17.90 million Net MarginsN/A Pretax MarginN/A Return on Equity-74.06% Return on Assets-55.31% Debt Debt-to-Equity RatioN/A Current Ratio2.34 Quick Ratio2.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.33 per share Price / Book0.69Miscellaneous Outstanding Shares40,117,000Free Float36,695,000Market Cap$9.11 million OptionableOptionable Beta0.60 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:HUGE) was last updated on 6/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredWhy July 22nd Could Mean Big Changes for Social SecurityIn a stunning move, President Trump has authorized an AI-led transformation of federal agencies, including Soc...Altimetry | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredBanks aren’t ready for this altcoin—are you?Donald Trump just fast-tracked TWO major crypto bills with an August deadline! Your window of opportunity i...Crypto 101 Media | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FSD Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share FSD Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.